MSTX Archives - Page 4 of 5 - Blue Horseshoe Stocks

PROW, REVI & Extended Watchlist

Progress Watch Corp. PROW
–
We first introduced PROW to our reports on December 20th, when it was trading at a low of .0065. At that time, we pointed out the likelihood of a Golden Cross, and witnessed one just a couple weeks later. That signaled what would turn out to be an astonishingly impressive week-long breakout to a high of .0488, a rise of 650% from our initial alert price. Quite a move, considering it only took a little over three weeks to transpire.

PROW, is also extremely relevant to yesterday’s report on REVI, because it illustrates the potential power of the elusive Golden Cross chart formation.

Resource Ventures, Inc. REVI

We were pleased with the quick-strike opportunity our alert on REVI offered us yesterday. After opening at its low of day (.0074) the stock surged to a subsequent high of .0105, affording sharp traders the chance at gains of up to 42% After receding from that initial push, the stock found support at .008, bouncing back to .009 before closing at .0087, up 17.5% on the day and trading over 30% more volume than its 3mo. average.

We consider that an extremely solid performance from a stock being mentioned in our reports for the first time, and our call of the possible bounce from the .0074-level couldn’t have been timed any better.

We’re not done following this play, however, as it appears this company is doing everything in its power to improve its process and ensure its positioning for positive growth in the future. We’ll leave the recent press highlights we outlined in yesterday’s special report intact below for anyone who might have missed it; we’re looking forward to seeing how the company follows through with everything it currently has in the works. We also have the impending Golden Cross angle to follow, as we mentioned above; REVI is even closer to its potential Golden Cross than PROW was when we first mentioned it. So the potential for further gains in the days and weeks to come is certainly present. While past performances are no guarantee of future results, we’ve seen the Golden Cross scenario play out so many times to a positive effect, that we would be remiss not to point it out.

We’re also looking at a fresh news release the company put out this morning:

SILVERADO CA–(Marketwired – Jan 22, 2014) – Resource Ventures, Inc. (PINKSHEETS: REVI) President Bob Thompson announced today that the Company’s wholly owned subsidiary, Resources Printing and Graphics, Inc. (RP&G) has achieved a milestone in their Promotional Products, in that the division has grown to represent more than 25% of the company’s overall revenue.

“15 years ago RP&G started their Promotional Products division to satisfy the many customer requests received on a daily basis, RP&G’s printing customers kept pressing us to take on more of their other graphic needs; they like the 24/7 service we offer, and just wanted us to do more for them,” said Bob Thompson, President of Resource Ventures Inc. “Now over a half million products are offered from pens to cups to watches; anything you want to put logo or message on, we can likely do.”

RECENT PRESS HIGHLIGHTS:

– Company expects to report over $2M in revenue for year ending 12/31/13, a year-over-year rise in in excess of 40-50% (Report due no later than 04/01)

– Planned exchange uplisting, process for which could begin as early as Q2

– Company has committed to timely release of all pertinent data while it remains on OTC Pink

– New online store “WikiClickPrint.com” in “fast-track development” mode

www.resourcesprinting.com

Extended Watchlist:
BBRY, KOOL, EVOK, MSTX, DRWI, MELA, CVM

PPHM, PLUG, & Extended Watchlist

Cannabis Sector Update

–

After an influx of new subscribers joined us over the weekend, we’d like to take this time to welcome our new friends, and try to get you up to speed as soon as possible. In a time that now spans three calendar years, we have been vigorously tracking numerous marijuana-related stocks with some very profitable results.

Last week (possibly aided by the first stores opening for sales of recreational marijuana in Colorado), the sector as a whole began to heat up once again, necessitating heavy discussion in our daily reports. As can be expected when several sessions of frenzied uptrending carries stocks as high as we saw many of our cannabis plays, several of those stocks began to consolidate on Friday.

The exceptions were GreenGrow Technologies, Inc. GRNH, and Hemp, Inc. HEMP; High volume spread over multi-day runs often leads to high volatility as well, as in the case with HEMP, which did consolidate to a low of .021, but followed that up with a rebound back to .032, a 52% intraday swing.

GRNH continued its run from the previous session where we had witnessed a low of .045, and barreled its way to a high of .124. We’ll take overnight gains in excess of 176% any day!

As for the rest of the pot stocks we’ve been tracking that have relaxed a bit, we are still eager to see how they respond this week, and will be on the lookout for any chances we might have at bounce plays. Additionally, news of how the first week of sales went in Colorado will be sure to get even more eyes turned toward this burgeoning market sector. Check back for future updates, as we stay tuned in every step of the way.

Peregrine Pharmaceuticals, Inc. PPHM

Speaking of stocks that we’ve been tracking since 2012, PPHM has proven itself a winner for us on multiple occasions over the years, and our most recent alert is turning out to be no different. Following that last mention, we observed a low 1.35, which at this morning’s pre-market high at 1.99 represents a 37% increase.

FDA-related news out this morning could fuel a serious push in a Northerly direction, so we won’t want to take our eyes off of PPHM for one moment as trading commences this morning.

TUSTIN, CA, Jan 06, 2014 (Marketwired via COMTEX) — Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced that the company has received Fast Track designation by the U.S. Food and Drug Administration (FDA) for its lead investigational immunotherapy bavituximab for the potential treatment of second-line non-small cell lung cancer (NSCLC).

“The fast track designation is a milestone for the SUNRISE trial program and represents a step closer to bringing bavituximab to the market,” said Robert Garnick, Ph.D., head of regulatory affairs at Peregrine. “We are very pleased that the FDA has recognized the potential of this novel therapy as a treatment for this serious and devastating type of cancer and look forward to working closely with them to ensure the most efficient review process.”

Plug Power, Inc. PLUG

Like the rest of the mentions in today’s newsletter, our history with PLUG goes back a long time. It has brought us percentage gains which cumulatively number in the thousands, and the New Year has brought new life for this one as well. This past Thursday, we caught PLUG at a low of 1.89, and were pleased at the solid 23% move it provided to 2.33. That figure is increasing this morning, as the stock is trading as high as 2.77 in pre-market action, a gain of 47% over Thursday’s low.

Extended Watchlist:
AMMX, PROW, EXMT, SIRI, TWGP, MSTX, SEED, CPRX, OXBT

CETV, VNDA, PHOT & Extended Watchlist

Central European Media Enterprises, Inc. CETV

We first caught CETV off of one of our From-4 scans back on May 10th. Time Warner had just purchased a block of shares worth close to $75M, and it caused us to take notice of the stock. At the time, we observed trades as low as 2.67.

As you can see on the chart below, CETV was on a fairly steady incline after that, recently (10/25) hitting a high of 6.60, a 147% move off of our observed bottom.

Shortly thereafter the stock would be subject to a big gap-down, and would continue to pull back to its current price in the low 2.00-range. The chart indicates that CETV is extremely oversold, and it has made higher lows over the past few sessions as it attempts to reverse its course. We want to keep our eyes peeled to this one, because conditions seem to be ripening for what could be a heck of a rebound.

Vanda Pharmaceuticals, Inc. VNDA

VNDA was a momentum play that we caught and included in yesterday’s extended watchlist. The company currently has a NDA (new drug application) filed with the FDA that treats chronic circadian arrhythmia.

After touching a low of 11.07 we saw a subsequent high of 13.49, a 22% intraday gain.

Growlife, Inc. PHOT

PHOT continues to be among our favorite medical/legal marijuana stocks, a play that we’ve followed for well over a year. Beginning at the end of August, trading at .0318, we realerted PHOT and began talking about it more and more. We posted another reminder on the 16th of September, and once again on October 22nd, when we mentioned that a golden cross on the chart was imminent.

During yesterday’s session PHOT hit .1029, which marks a 224% increase off of the bottom we observed in late August. Even those who missed that report, could have caught the stock as low as .042 following the 09/16 reminder, for up to a 125% gain at yesterday’s high. From the third report we mentioned (10/22), significant gains to the tune of 43% from .0719-.1029 could have been achieved.

Extended Watchlist:
VDSC, NURO, MSTX, FU, SUTR, YRCW(Huge gap down looking for reversal)
PBPB(Gapping up on positive earnings looking for continuation)

DCTH, ZLCS & Extended Watchlist

Delcath Systems, Inc. DCTH

Following its inclusion in yesterday morning’s extended watchlist, DCTH would go on to have a massively successful day of trading. The stock, after briefly touching a bottom at the .402-mark, went on an absolute tear as it reached a high .66 around lunchtime.

A single-session gain of 64% on the first day we placed DCTH on our watchlist is certainly nothing to sneeze at, and given the circumstances behind the upward surge, that may have only been the beginning.

The company received word from the FDA that its Primary Liver Disease treatment, ChemoSat, had received “orphan drug” designation, a classification which denotes a drug or procedure that is aimed at a disease which affects less than 200,000 people. About 26,000 Americans are diagnosed with Primary Liver Disease each year.

(Thomson Reuters ONE via COMTEX) — New York, NY – October 1, 2013 – Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology, announced today that the U.S. Food & Drug Administration (FDA) has granted the Company orphan drug designation for melphalan in the treatment of patients with hepatocellular carcinoma (HCC, or primary liver cancer). >>>FULL STORY

Side Note:
We rarely see stocks in this price range with an active options chain, but DCTH is an exception. The 12/21 .50 Calls jump out at us at first glance. If the stock were to approach a dollar between now and the expiration date, one could be looking at triple-digit gains.

Zalicus, Inc. ZLCS

Coincidentally, ZLCS, a stock that we’ve been following since the beginning of last month, also received a recent FDA orphan drug designation for its experimental Z160 drug, intended for the treatment of pain related to the Shingles.

Hitting a high of 1.38 yesterday, we finally saw ZLCS fill the gap on the chart that we had been pointing out for some time. Since we’ve been following ZLCS, we’ve seen a low of .78, and yesterday’s high represents a 77% gain off of that bottom. The filling of that gap was a pretty good indicator that it was time to take profits off of the table, so we certainly hope that folks were able to take advantage.

This morning, they also announced a reverse split, the result of which should be the stocks continued listing on the Nasdaq Capital Market, as it should enable shares to remain above the 1.00 minimum bid price required for listing. We would expect shares to come away from this split valued in the $6.00-range, and sure enough, we are seeing trades go off as high as 6.45 pre-market.

Zalicus Inc. (Nasdaq Capital Market: ZLCS) today announced that it has filed a Certificate of Amendment to its Sixth Amended and Restated Certificate of Incorporation, with the Secretary of State of the State of Delaware to effect a 1-for-6 reverse stock split of Zalicus common stock, effective as of October 3, 2013 at 12:01 a.m. Eastern Time…The reverse stock split will reduce the number of shares of common stock issued and outstanding from approximately 147.5 million to approximately 24.6 million. >>> FULL STORY

Extended Watchlist:

VICL, CRRS, CIMT, MNTG, RNN, MSTX

IWEB, TCPS, NRBT, BCRX & Extended Watchlist

IceWEB, Inc. IWEB

We have continued to follow IWEB since our first report on the stock on Tuesday July 9th. We observed nearly 100% in cumulative gains from the stock that week. Next, we saw a pullback to our initial alert price (.024), followed by several days of higher highs and higher lows. In fact, IWEB has steadily built back to yesterday’s high of .034, which is just .0015 below the recent swing high of .0355.

We hope to see IWEB break through to the next level, as it tests its previous resistance. A move past .0355 could signal another breakout from this stock so we most definitely want to keep it on our radars moving forward. As we can see on the chart above, several indicators appear to be bullish.

In addition, BARCHART.COM is currently listing IWEB with a 72% Overall “Buy” Rating, and a 100% Short-term “Buy” Rating

More Info : http://www.iceweb.com/

SIDE NOTE:

For those who may have missed yesterday’s afternoon update, we had a few solid gainers come off of yesterday morning’s report, which included TCPS, NRBT, and BCRX. We’ll want to keep an eye on those symbols today as well.

Extended Watchlist:
OWOO, LQMT, CSE, MSTX, CBMX,